false
0001429560
0001429560 2024-05-15
2024-05-15 iso4217:USD
xbrli:shares
iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May
15, 2024
TREVENA,
INC.
(Exact name of registrant as specified in its
charter)
Delaware
(State or other jurisdiction of incorporation)
| 001-36193 |
|
26-1469215 |
(Commission
File No.) |
|
(IRS
Employer
Identification No.) |
955
Chesterbrook Boulevard, Suite
110
Chesterbrook,
PA
19087
(Address of principal executive offices and zip
code)
Registrant’s telephone number, including
area code: (610)
354-8840
Not applicable
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of
each class | |
Trading
Symbol(s) | |
Name of
each exchange on which registered |
| Common
Stock, $0.001 par value | |
TRVN | |
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results
of Operations and Financial Condition. |
On May 15, 2024, Trevena, Inc. (the “Company”) issued
a press release announcing its financial results for the quarter ended March 31, 2024, and provided an overview of its 2024 year-to-date
operational highlights. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.
The information under this caption and contained in the press release
attached hereto as Exhibit 99.1 is furnished by the Company in accordance with Securities Exchange Commission Release No. 33-8216. This
information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act whether made before or after the date of this Current Report, except as shall be expressly set forth by specific reference in such
a filing.
| Item
3.01 | Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
As previously
disclosed, on March 6, 2024, the Company received a letter from Nasdaq stating that, for the last 30 consecutive business days,
the bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued inclusion on The
Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and that the Company
was not eligible for a second 180-day extension period because it did not comply with the $5,000,000 minimum stockholders’ equity
initial listing requirement for The Nasdaq Capital Market. As permitted under Nasdaq rules, the Company appealed Nasdaq’s determination
and requested a hearing before a Nasdaq Hearings Panel (the “Panel”). The hearing took place on May 2, 2024 (the “Appeal
Hearing”).
On April 5,
2024, the Company received an additional letter from Nasdaq notifying it that the Company no longer complied with the requirement under
Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing
on the Nasdaq Capital Market (the “Equity Standard Requirement”). At the Appeal Hearing, the Company presented its plan
to regain and maintain compliance with both the Minimum Bid Price Requirement and the Equity Standard Requirement.
On
May 13, 2024, the Company received a decision letter from the Panel granting it an extension until August 28, 2024, subject to certain
conditions, to regain compliance with the Nasdaq continued listing requirements, including the Minimum Bid Price Requirement and Equity
Standard Requirement. All delisting actions are stayed during the additional extension period granted by the Panel following the
Appeal Hearing. While the Company is investigating a range of options available to it to
regain compliance with the Minimum Bid Price Requirement and Equity Standard Requirement, there
can be no assurance that it will be able to regain compliance with the Nasdaq continued listing requirements before dates required by
Nasdaq or at all.
| Item 9.01. | Financial
Statements and Exhibits. |
(d)
Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
TREVENA, INC. |
| |
|
| Date: May 15, 2024 |
By: |
/s/
Barry Shin |
| |
|
Barry Shin |
| |
|
Executive
Vice President, Chief Operating Officer & Chief Financial Officer
|
Exhibit
99.1
Trevena
Reports First Quarter 2024 Results and Provides Business Update
TRV045,
novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
Ongoing
clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024
CHESTERBROOK,
Pa., May 15, 2024 (GLOBE NEWSWIRE) –Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization
of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the first quarter
ended March 31, 2024 and provided an overview of its recent operational highlights.
“TRV045
clinical development continued to progress in the first quarter, and we believe its novel MOA, once daily, oral dosing and favorable
tolerability profile, has the potential to address the significant unmet need for non-opioid therapies in pain and for novel mechanisms
in epilepsy” said Carrie Bourdow, President and CEO of Trevena.
First
Quarter 2024 and Recent Corporate Highlights
| · | TRV045
program. TRV045 previously demonstrated positive results in two proof-of-concept studies,
supporting further study in patients suffering from neuropathic pain and epilepsy. Across
all three completed Phase 1 studies, TRV045 has demonstrated a favorable tolerability profile,
and this has been consistent in the ongoing clinical PK study of the optimized formulation
of TRV045. Data from this clinical PK study, as well as the ongoing reproductive and sub-chronic
toxicology studies are expected in 2H 2024. The NIH-supported Epilepsy Therapy Screening
Program (ETSP) continues to study TRV045 in other in vivo epilepsy models, including exploring
TRV045 as a potential disease-modifying agent for the prevention of seizures, with data expected
in mid-2024. |
| · | OLINVYK
strategic review. The Company continues its review of strategic alternatives for OLINVYK.
There can be no assurance regarding the schedule for completion of the strategic review process,
that this strategic review process will result in the Company pursuing any transaction or
that any transaction, if pursued, will be completed. Potential strategic alternatives that
may be explored or evaluated include, but are not limited to, a sale, license, divestiture
or discontinuation of US commercial sales of OLINVYK. |
| · | Refocused
resources. Company continues in efforts to find efficiencies in operations, with recent
cost reductions totaling $3.5-$4.0 million on an annualized basis, including cost savings
from an approximately 35% reduction in force since year end 2023. |
Financial
Results and Other Updates for First Quarter 2024
For
the first quarter of 2024, the Company reported a net loss attributable to common stockholders of $7.7 million, or $0.36 per share, compared
to $7.8 million, or $0.81 per share in the first quarter of 2023. Cash and cash equivalents were $23.6 million as of March 31, 2024.
On
May 13, 2024, the Company received a decision letter from the Nasdaq Hearings Panel granting the
Company an extension until August 28, 2024, subject to certain conditions, to regain compliance with the Nasdaq continued listing requirements,
including the minimum bid price and shareholders’ equity requirements. All delisting actions are stayed during the additional
extension period granted by the Panel following the Appeal Hearing. While the Company is investigating
a range of options to regain compliance with the Nasdaq continued listing requirements, there can
be no assurance that the Company will be able to regain compliance before the dates required by Nasdaq or at all.
About
Trevena
Trevena,
Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults
for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates:
TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of
opioid use disorder.
For
more information, please visit www.Trevena.com
About
TRV045
TRV045
is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment
for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes
of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy.
S1P
receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating
neurotransmission and membrane excitability.
Trevena's
discovery efforts have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal
hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral
neuropathy. TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function
at or above pharmacologically active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the
FDA. Subjects in both studies referenced in this press release were enrolled outside of the United States, and the studies were not conducted
under the Investigational New Drug Application for TRV045.
About
OLINVYK® (oliceridine) injection
OLINVYK
is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, an opioid, which is a Schedule II controlled
substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe
enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg/1
mL and 2 mg/2 mL single-dose vials, and a 30 mg/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses
are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please
see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.
IMPORTANT
SAFETY INFORMATION
WARNING:
SERIOUS AND LIFE-THREATENING RISKS FROM USE
OF
OLINVYK
Addiction,
Abuse, and Misuse
Because
the use of OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and
death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors
and conditions.
Life-Threatening
Respiratory Depression
Serious,
life-threatening, or fatal respiratory depression may occur with use of OLINVYK, especially during initiation or following a dosage increase.
To reduce the risk of respiratory depression, proper dosing and titration of OLINVYK are essential.
Risks
From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant
use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation,
respiratory depression, coma, and death. Reserve concomitant prescribing of OLINVYK and benzodiazepines or other CNS depressants for
use in patients for whom alternative treatment options are inadequate.
Neonatal
Opioid Withdrawal Syndrome
If
opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening
if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.
INDICATIONS
AND USAGE
OLINVYK
is an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and
for whom alternative treatments are inadequate.
Limitations
of Use
Because
of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, reserve OLINVYK for use in patients
for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
| · | Have
not been tolerated or are not expected to be tolerated. |
| · | Have
not provided adequate analgesia or are not expected to provide adequate analgesia. |
The
cumulative total daily dose should not exceed 27 mg.
CONTRAINDICATIONS
OLINVYK
is contraindicated in patients with:
| · | Significant
respiratory depression |
| · | Acute
or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment |
| · | Known
or suspected gastrointestinal obstruction, including paralytic ileus |
| · | Known
hypersensitivity to oliceridine (e.g. anaphylaxis) |
WARNINGS
AND PRECAUTIONS
| · | OLINVYK
contains oliceridine, a Schedule II controlled substance, that exposes users to the risks
of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown,
it can occur in patients appropriately prescribed OLINVYK. Assess risk, counsel, and monitor
all patients receiving opioids. |
| · | Serious,
life-threatening respiratory depression has been reported with the use of opioids, even when
used as recommended, especially in patients with chronic pulmonary disease, or in elderly,
cachectic and debilitated patients. The risk is greatest during initiation of OLINVYK therapy,
following a dose increase, or when used with other drugs that depress respiration. Proper
dosing of OLINVYK is essential, especially when converting patients from another opioid product
to avoid overdose. Management of respiratory depression may include close observation, supportive
measures, and use of opioid antagonists, depending on the patient’s clinical status. |
| · | Opioids
can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related
hypoxemia with risk increasing in a dose-dependent fashion. In patients who present with
CSA, consider decreasing the dose of opioid using best practices for opioid taper. |
| · | Profound
sedation, respiratory depression, coma, and death may result from the concomitant use of
OLINVYK with benzodiazepines and/or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics,
anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other
opioids, or alcohol). Because of these risks, reserve concomitant prescribing of these drugs
for use in patients for whom alternative treatment options are inadequate, prescribe the
lowest effective dose, and minimize the duration. |
| · | Use
of OLINVYK for an extended period of time during pregnancy can result in withdrawal in the
neonate that may be life-threatening. Observe newborns for signs of neonatal opioid withdrawal
syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period
of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment
will be available. |
| · | OLINVYK
was shown to have mild QTc interval prolongation in thorough QT studies where patients were
dosed up to 27 mg. Total cumulative daily doses exceeding 27 mg per day were not studied
and may increase the risk for QTc interval prolongation. Therefore, the cumulative total
daily dose of OLINVYK should not exceed 27 mg. |
| · | Increased
plasma concentrations of OLINVYK may occur in patients with decreased Cytochrome P450 (CYP)
2D6 function or normal metabolizers taking moderate or strong CYP2D6 inhibitors; also in
patients taking a moderate or strong CYP3A4 inhibitor, in patients with decreased CYP2D6
function who are also receiving a moderate or strong CYP3A4 inhibitor, or with discontinuation
of a CYP3A4 inducer. These patients may require less frequent dosing and should be closely
monitored for respiratory depression and sedation at frequent intervals. Concomitant use
of OLINVYK with CYP3A4 inducers or discontinuation of a moderate or strong CYP3A4 inhibitor
can lower the expected concentration, which may decrease efficacy, and may require supplemental
doses. |
| · | Opioid-Induced
Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain,
or an increase in sensitivity to pain. This differs from tolerance where increasing doses
are required to maintain the desired effect. Symptoms of OIH include, but may not be limited
to, increased levels of pain upon dose increase, decreased levels of pain upon dose decrease,
or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only
if there is no evidence of disease progression, opioid tolerance, withdrawal, or addictive
behavior. If OIH is suspected, carefully consider appropriately decreasing the dose of the
current opioid analgesic or opioid rotation. |
| · | Cases
of adrenal insufficiency have been reported with opioid use (usually greater than one month).
Presentation and symptoms may be nonspecific and include nausea, vomiting, anorexia, fatigue,
weakness, dizziness, and low blood pressure. If confirmed, treat with physiologic replacement
doses of corticosteroids and wean patient from the opioid. |
| · | OLINVYK
may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory
patients. There is increased risk in patients whose ability to maintain blood pressure has
already been compromised by a reduced blood volume or concurrent administration of certain
CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients
for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as
it may cause vasodilation that can further reduce cardiac output and blood pressure. |
| · | Avoid
the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used
with caution in patients who may be susceptible to the intracranial effects of CO2
retention, such as those with evidence of increased intracranial pressure or brain tumors,
as a reduction in respiratory drive and the resultant CO2 retention can further
increase intracranial pressure. Monitor such patients for signs of sedation and respiratory
depression, particularly when initiating therapy. |
| · | As
with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases
in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis,
for worsening symptoms. |
| · | OLINVYK
may increase the frequency of seizures in patients with seizure disorders and may increase
the risk of seizures in vulnerable patients. Monitor patients with a history of seizure disorders
for worsened seizure control. |
| · | Do
not abruptly discontinue OLINVYK in a patient physically dependent on opioids. Gradually
taper the dosage to avoid a withdrawal syndrome and return of pain. Avoid the use of mixed
agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g.,
buprenorphine) analgesics in patients who are receiving OLINVYK, as they may reduce the analgesic
effect and/or precipitate withdrawal symptoms. |
| · | OLINVYK
may impair the mental or physical abilities needed to perform potentially hazardous activities
such as driving a car or operating machinery. |
| · | Although
self-administration of opioids by patient-controlled analgesia (PCA) may allow each patient
to individually titrate to an acceptable level of analgesia, PCA administration has resulted
in adverse outcomes and episodes of respiratory depression. Health care providers and family
members monitoring patients receiving PCA analgesia should be instructed in the need for
appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects
of opioid medications. |
ADVERSE
REACTIONS
Adverse
reactions are described in greater detail in the Prescribing Information.
The
most common (incidence ≥10%) adverse reactions in Phase 3 controlled clinical trials were nausea, vomiting, dizziness, headache, constipation,
pruritus, and hypoxia.
MEDICAL
INFORMATION
For
medical inquiries or to report an adverse event, other safety-related information or product complaints for a company product, please
contact the Trevena Medical Information Contact Center at 1-844-465-4686 or email MedInfo@Trevena.com.
You
are encouraged to report suspected adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
PLEASE
see www.OLINVYK.com for full prescribing information including BOXED warning and important safety information
Forward-Looking
Statements
Any
statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s
strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates
and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,
including: the expectations surrounding the continued advancement of the Company’s product pipeline; the potential safety and efficacy
of the Company’s product candidates and their regulatory and clinical development; the Company’s intention to pursue strategic
alternatives for OLINVYK and the ability of any such strategic alternative to provide shareholder value; the expected financial and operational
impacts of the Company’s decision to reduce commercial support for OLINVYK; the status, timing, costs, results and interpretation
of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties
inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s
assessment of discussions with FDA; available funding; uncertainties related to the Company’s intellectual property; uncertainties
related to other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates and
approved product; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from
time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as
of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However,
while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation
to do so, except as may be required by law.
For
more information, please contact:
Investor
Contact:
Dan
Ferry
Managing
Director
LifeSci
Advisors, LLC
daniel@lifesciadvisors.com
(617)
430-7576
Company
Contact:
Bob
Yoder
SVP,
Chief Business Officer & Head of Commercial Operations
Trevena,
Inc.
(610)
354-8840
TREVENA, INC.
Condensed Statements of Operations
(Unaudited, in thousands except share and per share data)
| | |
Three Months Ended Mar 31, | |
| | |
2024 | | |
2023 | |
| Product revenue | |
$ | 20 | | |
$ | 6 | |
| Total revenue | |
| 20 | | |
| 6 | |
| Operating expenses: | |
| | | |
| | |
| Cost of goods sold | |
| 88 | | |
| 127 | |
| Selling, general and administrative | |
| 5,845 | | |
| 6,089 | |
| Research and development | |
| 3,965 | | |
| 3,909 | |
| Total operating expenses | |
| 9,898 | | |
| 10,125 | |
| Loss from operations | |
| (9,878 | ) | |
| (10,119 | ) |
| Other income (expense) | |
| 2,200 | | |
| 2,300 | |
| Net loss | |
| (7,678 | ) | |
| (7,819 | ) |
| Unrealized gain on marketable securities | |
| - | | |
| 1 | |
| Comprehensive loss | |
$ | (7,678 | ) | |
$ | (7,818 | ) |
| Per share information: | |
| | | |
| | |
| Net loss per share of common stock, basic and diluted | |
$ | (0.36 | ) | |
$ | (0.81 | ) |
| Weighted average shares outstanding, basic and diluted | |
| 21,303,390 | | |
| 9,594,072 | |
TREVENA, INC.
Condensed Balance Sheets
(Unaudited, in thousands)
| | |
March 31, 2024 | | |
December 31,
2023 | |
| Assets | |
| | | |
| | |
| Current assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 23,552 | | |
$ | 32,975 | |
| Prepaid expenses and other current assets | |
| 2,426 | | |
| 2,230 | |
| Total current assets | |
| 25,978 | | |
| 35,205 | |
| Restricted cash | |
| 540 | | |
| 540 | |
| Property and equipment, net | |
| 1,107 | | |
| 1,195 | |
| Right-of-use lease assets | |
| 3,512 | | |
| 3,665 | |
| Total assets | |
$ | 31,137 | | |
$ | 40,605 | |
| Liabilities and stockholders’ (deficit) equity | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable, net | |
$ | 2,327 | | |
$ | 2,303 | |
| Accrued expenses and other current liabilities | |
| 3,839 | | |
| 4,239 | |
| Current portion of lease liabilities | |
| 1,041 | | |
| 1,012 | |
| Total current liabilities | |
| 7,207 | | |
| 7,554 | |
| Loans payable, net | |
| 31,317 | | |
| 30,809 | |
| Leases, net of current portion | |
| 4,153 | | |
| 4,424 | |
| Warrant liability | |
| 3,114 | | |
| 5,475 | |
| Total liabilities | |
| 45,791 | | |
| 48,262 | |
| | |
| | | |
| | |
| Common stock | |
| 18 | | |
| 17 | |
| Additional paid-in capital | |
| 581,067 | | |
| 580,387 | |
| Accumulated deficit | |
| (595,739 | ) | |
| (588,061 | ) |
| Total stockholders’ (deficit) equity | |
| (14,654 | ) | |
| (7,657 | ) |
| Total liabilities and stockholders’ (deficit) equity | |
$ | 31,137 | | |
$ | 40,605 | |
v3.24.1.1.u2
Cover
|
May 15, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
May 15, 2024
|
| Entity File Number |
001-36193
|
| Entity Registrant Name |
TREVENA,
INC.
|
| Entity Central Index Key |
0001429560
|
| Entity Tax Identification Number |
26-1469215
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
955
Chesterbrook Boulevard
|
| Entity Address, Address Line Two |
Suite
110
|
| Entity Address, City or Town |
Chesterbrook
|
| Entity Address, State or Province |
PA
|
| Entity Address, Postal Zip Code |
19087
|
| City Area Code |
610
|
| Local Phone Number |
354-8840
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
Stock, $0.001 par value
|
| Trading Symbol |
TRVN
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Trevena (NASDAQ:TRVN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Trevena (NASDAQ:TRVN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
